11 unchanged sentences
Purchased Under
−Removed: January 1, 2023 - January 31, 2023 844 (1)
+Added: April 1, 2023 - April 30, 2023 1,006 (1)
— $4,808,991,028
−Removed: February 1, 2023 - February 28, 2023 7,306,847 (1)
+Added: May 1, 2023 - May 31, 2023 1,105 (1)
— $4,808,991,028
−Removed: March 1, 2023 - March 31, 2023 3,035,907 (1)
+Added: June 1, 2023 - June 30, 2023 1,194 (1)
— $4,808,991,028
1 unchanged sentence
— $4,808,991,028 (2)
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 844 in January;
−Removed: 1,015 in February;
−Removed: and 926 in March.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,006 in April;
+Added: 1,105 in May;
+Added: and 1,194 in June.
On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
+Added: (c) Director and Officer Trading Arrangements
+Added: During the three months ended June 30, 2023, no director or officer of the company adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
2023 Form 10-Q |
1 unchanged sentence
Exhibit Description
−Removed: Form of AbbVie Inc.
−Removed: Performance-Vested Restricted Stock Unit Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Performance Share Award Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Non-Employee Director RSU Agreement (US)*
−Removed: Form of AbbVie Inc.
−Removed: Non-Qualified Stock Option Agreement*
−Removed: Form of AbbVie Inc.
−Removed: Retention RSU Agreement - Ratable Vesting*
−Removed: Form of AbbVie Inc.
−Removed: Non-Employee Directors’ Fee Plan, as amended and restated*
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, filed on May 5, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 7, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
7 unchanged sentences
_______________________________________________________________________________
−Removed: * Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
2023 Form 10-Q |
2 unchanged sentences
Chief Financial Officer (Principal Financial Officer)
+Added: August 7, 2023
2023 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.